BMO Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $94
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains an Outperform rating on Gilead Sciences and raises the price target from $85 to $94.
October 17, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has increased its price target for Gilead Sciences from $85 to $94 while maintaining an Outperform rating, indicating positive expectations for the stock.
The increase in price target from $85 to $94 by BMO Capital suggests a positive outlook for Gilead Sciences. Maintaining an Outperform rating indicates confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100